ATRA (STOCKS)
Atara Biotherapeutics, Inc
$4.600000
-0.230000 (-4.76%)
Prev close: $4.830000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Anhco Nguyen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $33.24M
- Employees
- 38
- P/E (TTM)
- 2.20
- P/B (TTM)
- -0.90
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
1
Buy
4
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.32 | $-0.88 | +0.5572 | +63.52% |
|
Jun 2025 (Q2)
|
$0.19 | $-0.47 | +0.6592 | +140.49% |
|
Mar 2025 (Q1)
|
$3.50 | $-2.02 | +5.5193 | +273.33% |
|
Dec 2024 (Q4)
|
$-1.19 | $-3.65 | +2.4575 | +67.37% |
Financial Statements
| Revenues | $151.93M |
| Benefits Costs and Expenses | $128.52M |
| Costs And Expenses | $125.71M |
| Operating Expenses | $125.71M |
| Depreciation and Amortization | $3.17M |
| Research and Development | $66.39M |
| Other Operating Expenses | $56.19M |
| Operating Income/Loss | $26.22M |
| Income/Loss From Continuing Operations After Tax | $23.40M |
| Income/Loss From Continuing Operations Before Tax | $23.41M |
| Income Tax Expense/Benefit | $12.00K |
| Interest Expense, Operating | $3.92M |
| Net Income/Loss | $23.40M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $23.40M |
| Net Income/Loss Available To Common Stockholders, Basic | $23.40M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.89 |
| Diluted Earnings Per Share | $2.86 |
| Basic Average Shares | 13,259,000 |
| Diluted Average Shares | 13,393,000 |
| Assets | $30.17M |
| Current Assets | $18.43M |
| Inventory | $0.00 |
| Noncurrent Assets | $11.74M |
| Fixed Assets | $147.00K |
| Other Non-current Assets | $11.59M |
| Liabilities | $66.80M |
| Current Liabilities | $18.06M |
| Accounts Payable | $318.00K |
| Wages | $2.07M |
| Other Current Liabilities | $15.67M |
| Noncurrent Liabilities | $48.74M |
| Equity | -$36.63M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$36.63M |
| Liabilities And Equity | $30.17M |
| Net Cash Flow From Operating Activities | -$69.71M |
| Net Cash Flow From Operating Activities, Continuing | -$69.71M |
| Net Cash Flow From Investing Activities | $13.08M |
| Net Cash Flow From Investing Activities, Continuing | $13.08M |
| Net Cash Flow From Financing Activities | $15.77M |
| Net Cash Flow From Financing Activities, Continuing | $15.77M |
| Net Cash Flow | -$40.86M |
| Net Cash Flow, Continuing | -$40.86M |
| Comprehensive Income/Loss | $23.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $23.38M |
| Other Comprehensive Income/Loss | -$12.00K |